Background: 1-3, 1-6 β-glucan derived from Baker’s yeast (Saccharomyces cerevisiae) has been widely studied for its immune stimulatory capabilities and safety. Previous studies found β-glucan to have efficacy at re...Background: 1-3, 1-6 β-glucan derived from Baker’s yeast (Saccharomyces cerevisiae) has been widely studied for its immune stimulatory capabilities and safety. Previous studies found β-glucan to have efficacy at reducing incidence of URTIs as well as being a low risk for negative side effects. The current study aimed to examine the effects of yeast β-glucan (Angel Yeast) on cold and flu incidences and symptoms in healthy adults. Methods: Two hundred and thirty-one males and females aged 18 to 65 years old supplemented with either β-glucan or a placebo for 3-months. Participants completed a general health questionnaire every 4 weeks and in addition, if participants experienced any cold or flu symptoms, these were recorded daily (along with severity) until resolved or up to 2 weeks. Results: Supplementation with β-glucan reduced the self-reported severity of sore throats and improved sleep quality compared to the placebo group. Conclusions: Yeast β-glucan supplementation appears to be able to help reduce certain symptoms experienced during a cold or flu episode and is safe and well tolerated.展开更多
This study aimed to investigate the effects of dietary supplementation of yeast 13-glucan on the nutrient digestibility and serum profiles in pre-ruminant Holstein calves. Forty-two neonatal Holstein calves （（39.6＋...This study aimed to investigate the effects of dietary supplementation of yeast 13-glucan on the nutrient digestibility and serum profiles in pre-ruminant Holstein calves. Forty-two neonatal Holstein calves （（39.6＋4.2） kg） were randomly allotted to six groups, and each was offered one of the following diets： a basal diet （control） or the basal diet supplemented with 25, 50, 75, 100 or 200 mg of yeast 13-glucan kg-~ feed （dry matter basis）. The basal diet consisted of a milk replacer and a starter feed. The trial lasted for 56 d. Two digestibility trials were conducted from d 14 to 20 and from d 42 to 48. Blood samples were collected on d 0, 14, 28 and 42 for serum profile analyses. On d 56, three calves from each group were slaughtered, and intestinal samples were collected to assess the villous height, crypt depth and mucosal thickness. Although feed intake was not affected by dietary treatment （P〉0.05）, the average daily gain （ADG） and gain-to-feed ratios were higher （P〈0.05） for the calves fed 75 mg of yeast β-glucan kg^-1 feed than those in the other groups. The supplementation of yeast β-glucan at 75 mg kg^-1 feed increased the apparent digestibility of dry matter （DM）, crude protein （CP）, ether extract （EE）, and phosphorus （P） （P〈0.05） and the ratio of intestinal villous height to crypt depth （V/C） （P〈0.05） when compared with the control group. No effects of yeast β-glucan on the serum concentrations of total protein （TP）, albumin （ALB）, serum urea nitrogen （SUN） and glucose （GLU） were observed （P〉0.05）. Compared with the control group, supplementation of yeast β-glucan decreased （P〈0.05） the serum concentrations of triglycerides （TG） and total cholesterol （TC）. The serum concentration of immunoglobulin G （IgG） and immunoglobulin M （IgM） increased quadratically （P〈0.05）, whereas the serum concentration of immunoglobulin A （IgA） was unaffected by dietary treatments （P〉0.05）. The supplementation of yeast β-glucan stimu- lated the enzymatic activity of alkaline phosphatase （ALP） （P〈0.05） compared with the control group. The lysozyme （LYZ） concentration increased quadratically （P〈0.05） with increasing yeast β-glucan levels. The results suggested that dietary supplementation of yeast 13-glucan at 75 mg kg^-1 feed improved nutrient digestibility, enhanced immunity by increasing the immunoglobulin concentration and stimulating ALP, and exerted no adverse effects on metabolism in pre-ruminant calves.展开更多
Purpose: In a placebo-controlled, double-blind, randomized clinical trial, the effect of an insoluble yeast beta-glucan preparation on the incidences of common colds and its effect on common cold symptoms were compare...Purpose: In a placebo-controlled, double-blind, randomized clinical trial, the effect of an insoluble yeast beta-glucan preparation on the incidences of common colds and its effect on common cold symptoms were compared to placebo. Methods: 100 healthy participants with recurring infections were randomly assigned to receive either placebo or yeast beta-glucan (Yestimun?;n = 50 each group) over a period of 26 weeks. The subjects had to document each common cold episode in a diary, and rate 6 predefined infections symptoms on a 3-point rating scale during an infection period, resulting in an infection score. The common cold episodes were confirmed by the investigators. Results: A total of 171 common cold episodes were documented. Of these, 76 were experienced by 38 subjects in the beta-glucan group and 96 were experienced by 48 subjects in the placebo group (p = 0.406). The beta-glucan group had significantly more subjects without incidences of common cold than the placebo group (15.6% vs 2.0%;p = 0.019). During the most intense infection season (first 13 weeks of the study), the beta-glucan group had significantly less infections compared to placebo (p = 0.02). Beta-glucan significantly reduced the typical cold symptoms (“sore throat and/or difficulty swallowing”, “hoarseness and/or cough” and “runny nose”) as opposed to placebo. Conclusion: The present study demonstrates a prophylactic effect of yeast beta-glucan on the occurrence of common colds as opposed to placebo. In addition, when these episodes occurred, they were from the beginning less pronounced and subsided faster.展开更多
β-glucans are bioactive compounds with a wide range of biological properties, including anticancer, anti-inflammatory, antioxidant, and immune-modulating properties. Due to their specific physical properties, such as...β-glucans are bioactive compounds with a wide range of biological properties, including anticancer, anti-inflammatory, antioxidant, and immune-modulating properties. Due to their specific physical properties, such as (in)solubility, viscosity, and gelation, β-glucans are increasingly being used in the food, pharmaceutical, and cosmetic industries. The purpose of this review is to provide an overview of the different types of β-glucans, their sources, especially Saccharomyces cerevisiae yeasts, and the methods of extraction, isolation, and purification of β-glucans, with the aim of optimizing these methods for the efficient production process. Moreover, the physico-chemical properties, modifications, current applications and future prospects of the use of β-glucans in food, medicines, cosmetics and other potential value-added products are summarized. The data presented indicate that β-glucans will play an increasingly important role in the sector of special-purpose food products as well as in other current and future areas.展开更多
文摘Background: 1-3, 1-6 β-glucan derived from Baker’s yeast (Saccharomyces cerevisiae) has been widely studied for its immune stimulatory capabilities and safety. Previous studies found β-glucan to have efficacy at reducing incidence of URTIs as well as being a low risk for negative side effects. The current study aimed to examine the effects of yeast β-glucan (Angel Yeast) on cold and flu incidences and symptoms in healthy adults. Methods: Two hundred and thirty-one males and females aged 18 to 65 years old supplemented with either β-glucan or a placebo for 3-months. Participants completed a general health questionnaire every 4 weeks and in addition, if participants experienced any cold or flu symptoms, these were recorded daily (along with severity) until resolved or up to 2 weeks. Results: Supplementation with β-glucan reduced the self-reported severity of sore throats and improved sleep quality compared to the placebo group. Conclusions: Yeast β-glucan supplementation appears to be able to help reduce certain symptoms experienced during a cold or flu episode and is safe and well tolerated.
基金supported by the Earmarked Fund for Beijing Dairy Industry Innovation Teamthe Beijing Key Technology for Early Weaning of Calvesthe National Key Technology R&D Program of China (2012BAD12B06)
文摘This study aimed to investigate the effects of dietary supplementation of yeast 13-glucan on the nutrient digestibility and serum profiles in pre-ruminant Holstein calves. Forty-two neonatal Holstein calves （（39.6＋4.2） kg） were randomly allotted to six groups, and each was offered one of the following diets： a basal diet （control） or the basal diet supplemented with 25, 50, 75, 100 or 200 mg of yeast 13-glucan kg-~ feed （dry matter basis）. The basal diet consisted of a milk replacer and a starter feed. The trial lasted for 56 d. Two digestibility trials were conducted from d 14 to 20 and from d 42 to 48. Blood samples were collected on d 0, 14, 28 and 42 for serum profile analyses. On d 56, three calves from each group were slaughtered, and intestinal samples were collected to assess the villous height, crypt depth and mucosal thickness. Although feed intake was not affected by dietary treatment （P〉0.05）, the average daily gain （ADG） and gain-to-feed ratios were higher （P〈0.05） for the calves fed 75 mg of yeast β-glucan kg^-1 feed than those in the other groups. The supplementation of yeast β-glucan at 75 mg kg^-1 feed increased the apparent digestibility of dry matter （DM）, crude protein （CP）, ether extract （EE）, and phosphorus （P） （P〈0.05） and the ratio of intestinal villous height to crypt depth （V/C） （P〈0.05） when compared with the control group. No effects of yeast β-glucan on the serum concentrations of total protein （TP）, albumin （ALB）, serum urea nitrogen （SUN） and glucose （GLU） were observed （P〉0.05）. Compared with the control group, supplementation of yeast β-glucan decreased （P〈0.05） the serum concentrations of triglycerides （TG） and total cholesterol （TC）. The serum concentration of immunoglobulin G （IgG） and immunoglobulin M （IgM） increased quadratically （P〈0.05）, whereas the serum concentration of immunoglobulin A （IgA） was unaffected by dietary treatments （P〉0.05）. The supplementation of yeast β-glucan stimu- lated the enzymatic activity of alkaline phosphatase （ALP） （P〈0.05） compared with the control group. The lysozyme （LYZ） concentration increased quadratically （P〈0.05） with increasing yeast β-glucan levels. The results suggested that dietary supplementation of yeast 13-glucan at 75 mg kg^-1 feed improved nutrient digestibility, enhanced immunity by increasing the immunoglobulin concentration and stimulating ALP, and exerted no adverse effects on metabolism in pre-ruminant calves.
文摘Purpose: In a placebo-controlled, double-blind, randomized clinical trial, the effect of an insoluble yeast beta-glucan preparation on the incidences of common colds and its effect on common cold symptoms were compared to placebo. Methods: 100 healthy participants with recurring infections were randomly assigned to receive either placebo or yeast beta-glucan (Yestimun?;n = 50 each group) over a period of 26 weeks. The subjects had to document each common cold episode in a diary, and rate 6 predefined infections symptoms on a 3-point rating scale during an infection period, resulting in an infection score. The common cold episodes were confirmed by the investigators. Results: A total of 171 common cold episodes were documented. Of these, 76 were experienced by 38 subjects in the beta-glucan group and 96 were experienced by 48 subjects in the placebo group (p = 0.406). The beta-glucan group had significantly more subjects without incidences of common cold than the placebo group (15.6% vs 2.0%;p = 0.019). During the most intense infection season (first 13 weeks of the study), the beta-glucan group had significantly less infections compared to placebo (p = 0.02). Beta-glucan significantly reduced the typical cold symptoms (“sore throat and/or difficulty swallowing”, “hoarseness and/or cough” and “runny nose”) as opposed to placebo. Conclusion: The present study demonstrates a prophylactic effect of yeast beta-glucan on the occurrence of common colds as opposed to placebo. In addition, when these episodes occurred, they were from the beginning less pronounced and subsided faster.
文摘β-glucans are bioactive compounds with a wide range of biological properties, including anticancer, anti-inflammatory, antioxidant, and immune-modulating properties. Due to their specific physical properties, such as (in)solubility, viscosity, and gelation, β-glucans are increasingly being used in the food, pharmaceutical, and cosmetic industries. The purpose of this review is to provide an overview of the different types of β-glucans, their sources, especially Saccharomyces cerevisiae yeasts, and the methods of extraction, isolation, and purification of β-glucans, with the aim of optimizing these methods for the efficient production process. Moreover, the physico-chemical properties, modifications, current applications and future prospects of the use of β-glucans in food, medicines, cosmetics and other potential value-added products are summarized. The data presented indicate that β-glucans will play an increasingly important role in the sector of special-purpose food products as well as in other current and future areas.
